NCT06185751View on ClinicalTrials.gov

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2040

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

WS-CART-CS1

-Subject will be hospitalized for 7 days

DRUG

Lymphodepleting chemotherapy

"* Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3"

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Paula C. & Rodger O. Riney Blood Cancer Research

UNKNOWN

lead

Washington University School of Medicine

OTHER